Evidence map›Paper›PMID 42865502›Full record

ArticleFrontiers in neuroscience2026

Analytical validation of digital measure of intelligibility in progressive supranuclear palsy.

İlkay Yıldız Potter, Ram Kinker Mishra, Tejas Pawar, Jesse Wang, Antje S Mefferd, Michael de Riesthal, Mili Kuruvilla-Dugdale, Anne-Marie Wills, Alexander Pantelyat, Ashkan Vaziri

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

İlkay Yıldız PotterBioSensics LLC, Newton, MA, United States.
Ram Kinker MishraBioSensics LLC, Newton, MA, United States.
Tejas PawarBioSensics LLC, Newton, MA, United States.
Jesse WangDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Antje S MefferdVanderbilt University Medical Center, Nashville, TN, United States.
Michael de RiesthalVanderbilt University Medical Center, Nashville, TN, United States.
Mili Kuruvilla-DugdaleDepartment of Communication Sciences and Disorders, University of Iowa, Iowa City, IA, United States.
Anne-Marie WillsDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Alexander PantelyatDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Ashkan VaziriBioSensics LLC, Newton, MA, United States.

Funding

Digital Health Technologies for Monitoring Motor Function in Progressive Supranuclear Palsy and Dementia with Lewy BodiesUF1AG094587 · NIA · BIOSENSICS, LLC · PI PANTELYAT, ALEXANDER Y., VAZIRI, ASHKAN · 2025 to 2025
$5.2M
Phase IIB: A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration SyndromesR44AG080861 · NIA · BIOSENSICS, LLC · PI ADAM L. BOXER, Irene Litvan · 2022 to 2026
$3.5M
NIA NIH HHS R44 AG080861NIA NIH HHS UF1 AG094587
6 · The paper itself

Abstract

Introduction: Progressive supranuclear palsy (PSP) causes progressive speech impairment. Digital speech analysis can objectively and remotely quantify measures like intelligibility, typically judged subjectively by experts during clinical visits. The objective of this study is to validate digital intelligibility measurement in PSP via BioDigit Speech (BioSensics LLC, United States). Methods: Forty-nine PSP patients performed standardized passage-reading scored by BioDigit Speech and three experts (18 + years of experience); expert mean score (EMS) served as the reference standard. Results: Digital intelligibility showed high correlation and agreement with EMS ( Conclusion: Collected remotely with minimal burden, digital speech measures like intelligibility may serve as objective, sensitive outcomes for communication-focused interventions and PSP trials.

Indexed as

digital healthdysarthriaintelligibilityprogressive supranuclear palsyspeech analysis and processing

Identifiers

PMID42865502
PMCPMC13655066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.